Effect of disease states on theophylline elimination
- PMID: 3534054
- DOI: 10.1016/0091-6749(86)90053-9
Effect of disease states on theophylline elimination
Abstract
Host factors play an important role in the dosing requirements of theophylline. Theophylline metabolism and clearance depend principally on liver cell function rather than on hepatic flow. The effects of acute hypoxemia require more study; however, patients with chronic obstructive pulmonary disease who have chronic hypoxemia appear to have some impairment of clearance. Clearance is variably and sometimes drastically reduced in patients with liver disease and heart failure, and is reduced by some viral infections. It is not impaired by renal failure. Current split-virus vaccine mixtures do not appear to affect clearance. Clearance is increased in patients with cystic fibrosis and hyperthyroidism. The depressed clearance seen in the severely ill patients who require intensive care improves with improvement in the patient's condition, but the individual factors involved have not been identified. An area requiring more study is the effect of pH on the apparent distribution volume for theophylline. In the presence of liver disease, heart failure, or serious illness, caution must be applied in theophylline dosing, with frequent monitoring of serum levels. Stable patients also warrant an initially conservative dose until serum levels are obtained to guide further dose adjustments.
Similar articles
-
Influenza vaccination and theophylline pharmacokinetics in patients with chronic obstructive lung disease.West J Med. 1983 Nov;139(5):651-4. West J Med. 1983. PMID: 6659488 Free PMC article.
-
Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia.Am Rev Respir Dis. 1986 Jun;133(6):1110-4. doi: 10.1164/arrd.1986.133.6.1110. Am Rev Respir Dis. 1986. PMID: 3717762 Clinical Trial.
-
The effect of split virus influenza vaccination on theophylline pharmacokinetics.Am Rev Respir Dis. 1985 Jun;131(6):934-8. doi: 10.1164/arrd.1985.131.6.934. Am Rev Respir Dis. 1985. PMID: 2408526
-
Update on the pharmacodynamics and pharmacokinetics of theophylline.Chest. 1985 Aug;88(2 Suppl):103S-111S. doi: 10.1378/chest.88.2_supplement.103s. Chest. 1985. PMID: 3893922 Review.
-
Hypoxia, arterial pH and theophylline disposition.Clin Pharmacokinet. 1993 Oct;25(4):283-99. doi: 10.2165/00003088-199325040-00004. Clin Pharmacokinet. 1993. PMID: 8261713 Review.
Cited by
-
The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.Eur J Clin Pharmacol. 1988;35(4):357-62. doi: 10.1007/BF00561364. Eur J Clin Pharmacol. 1988. PMID: 3197743
-
The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.Clin Pharmacokinet. 1988 Jun;14(6):347-73. doi: 10.2165/00003088-198814060-00003. Clin Pharmacokinet. 1988. PMID: 3293870 Review.
-
A composite screening tool for medication reviews of outpatients: general issues with specific examples.Drugs Aging. 2007;24(9):733-60. doi: 10.2165/00002512-200724090-00003. Drugs Aging. 2007. PMID: 17727304 Review.
-
Effect of theophylline on serum and milk pharmacokinetics of tylosin following intramuscular administration in lactating goats.BMC Vet Res. 2024 Jun 8;20(1):251. doi: 10.1186/s12917-024-04089-6. BMC Vet Res. 2024. PMID: 38849822 Free PMC article.
-
The pharmacological approach to the elderly COPD patient.Drugs Aging. 2013 Jul;30(7):479-502. doi: 10.1007/s40266-013-0080-1. Drugs Aging. 2013. PMID: 23580319 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources